Deregulated estrogen receptor α and p53 heterozygosity collaborate in the development of mammary hyperplasia

Cancer Research

Volumn 70, Issue 10, 2010, Pages 3965-3974

  Díaz Cruz, Edgar S ^a   Furth, Priscilla A ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ESTROGEN RECEPTOR ALPHA; GLYCOPROTEIN P; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN P27; PROTEIN P53; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST HYPERPLASIA; CANCER RISK; CELL PROLIFERATION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION REGULATION; HETEROZYGOSITY; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE; P53 GENE; PRECANCER; PREVALENCE; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; FEMALE; HETEROZYGOTE; IMMUNOENZYME TECHNIQUES; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PARITY; PRECANCEROUS CONDITIONS; PREGNANCY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952848351     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3450     Document Type: Article

References (50)

1. Glass AG, Lacey JV, Jr., Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152-1161
2. Lakhani S.R. The transition from hyperplasia to invasive carcinoma of the breast Journal of Pathology 1999 187 3 272-278 DOI 10.1002/(SICI)1096- 9896(199902)187:3<272::AID-PATH265>3.0.CO;2-2 2. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999;187:272-278 (Pubitemid 29064150)
3. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006;13:293-325.
4. Varley J.M. Brammar W.J. Lane D.P. Swallow J.E. Dolan C. Walker R.A. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas Oncogene 1991 6 3 413-421 4. Varley JM, Brammar WJ, Lane DP, Swallow JE, Dolan C, Walker RA. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 1991;6:413-421 (Pubitemid 21924097)
5. Elledge R.M. Allred D.C. The p53 tumor suppressor gene in breast cancer Breast Cancer Research and Treatment 1994 32 1 39-47 DOI 10.1007/BF00666204 5. Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994;32:39-47. (Pubitemid 24322246)
6. Rudas M. Neumayer R. Gnant M.F.X. Mittelbock M. Jakesz R. Reiner A. p53 Protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast European Journal of Cancer Part A 1997 33 1 39-44 DOI 10.1016/S0959-8049(96)00368-1, PII S0959804996003681 6. Rudas M, Neumayer R, Gnant MF, Mittelbock M, Jakesz R, Reiner A. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 1997;33:39-44. (Pubitemid 27099565)
7. Mommers E.C.M. Leonhart A.M. Falix F. Michalides R. Meijer C.J.L.M. Baak J.P.A. Van Diest P.J. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade Journal of Pathology 2001 194 3 327-333 DOI 10.1002/path.910 7. Mommers EC, Leonhart AM, Falix F, et al. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol 2001;194:327-333 (Pubitemid 32624559)
8. Warnberg F. Nordgren H. Bergkvist L. Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness British Journal of Cancer 2001 85 6 869-874 DOI 10.1054/bjoc.2001.1995 8. Warnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 2001;85:869-874 (Pubitemid 33010555)
9. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res 2002;4:70-76
10. Rohan T.E. Hartwick W. Miller A.B. Kandel R.A. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk Journal of the National Cancer Institute 1998 90 17 1262-1269 10. Rohan TE, Hartwick W, Miller AB, Kandel RA. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 1998;90:1262-1269 (Pubitemid 28433470)
11. Mack L. Kerkvliet N. Doig G. O'Malley F.P. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67 Human Pathology 1997 28 8 974-979 DOI 10.1016/S0046-8177(97)90014-9 11. Mack L, Kerkvliet N, Doig G, O'Malley FP. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. Hum Pathol 1997;28:974-979 (Pubitemid 27355559)
12. Hieken T.J. Cheregi J. Farolan M. Kim J. Velasco J.M. Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up American Journal of Surgery 2007 194 4 504-506 DOI 10.1016/j.amjsurg.2007.07.002, PII S0002961007005582 12. Hieken TJ, Cheregi J, Farolan M, Kim J, Velasco JM. Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up. Am J Surg 2007;194:504-506 (Pubitemid 47361063)
13. de Roos M.A. de Bock G.H. de Vries J. van der Vegt B. Wesseling J. p53 Overexpression is a Predictor of Local Recurrence After Treatment for Both in situ and Invasive Ductal Carcinoma of the Breast Journal of Surgical Research 2007 140 1 109-114 DOI 10.1016/j.jss.2006.10.045, PII S002248040600583X 13. de Roos MA, de Bock GH, de Vries J, van der Vegt B, Wesseling J. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. J Surg Res 2007;140:109-114 (Pubitemid 46669545)
14. Greenblatt M.S. Bennett W.P. Hollstein M. Harris C.C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis Cancer Research 1994 54 18 4855-4878 14. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878 (Pubitemid 24289415)
15. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810
16. Malkin D. Li F.P. Strong L.C. Fraumeni J.F. Jr. Nelson C.E. Kim D.H. Kassel J. Gryka M.A. Bischoff F.Z. Tainsky M.A. Friend S.H. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms Science 1990 250 4985 1233-1238 16. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-1238 (Pubitemid 120031831)
17. Varley J.M. Evans D.G.R. Birch J.M. Li-Fraumeni syndrome - A molecular and clinical review British Journal of Cancer 1997 76 1 1-14 17. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome - a molecular and clinical review. Br J Cancer 1997;76:1-14. (Pubitemid 27250068)
18. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003;21:28-34.
19. Khan S.A. Rogers M.A.M. Khurana K.K. Meguid M.M. Numann P.J. Estrogen receptor expression in benign breast epithelium and breast cancer risk Journal of the National Cancer Institute 1998 90 1 37-42 19. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 1998;90:37-42. (Pubitemid 28078079)
20. Frech MS, Halama ED, Tilli MT, et al. Deregulated estrogen receptor α expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res 2005;65:681-685
21. Kelsey JL, Gammon MD. The epidemiology of breast cancer. CA Cancer J Clin 1991;41:146-165
22. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer Journal of Mammary Gland Biology and Neoplasia 2002 7 1 3-15 DOI 10.1023/A:1015714305420 22. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 2002;7:3-15. (Pubitemid 38420778)
23. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer. N Engl J Med 1992;327:319-328
24. Medina D, Kittrell FS. p53 function is required for hormone-mediated protection of mouse mammary tumorigenesis. Cancer Res 2003;63:6140-6143
25. Sivaraman L, Conneely OM, Medina D, O'Malley B. p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc Natl Acad Sci U S A 2001;98:12379-12384
26. Dunphy KA, Blackburn AC, Yan H, O'Connell LR, Jerry DJ. Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/- mice. Breast Cancer Res 2008;10:R43.
27. Putti TC, El-Rehim DM, Rakha EA, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005;18:26-35.
28. Medina D, Kittrell FS, Shepard A, et al. Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J 2002;16:881-883
29. Medina D. Kittrell F.S. Shepard A. Contreras A. Rosen J.M. Lydon J. Hormone dependence in premalignant mammary progression Cancer Research 2003 63 5 1067-1072 29. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM, Lydon J. Hormone dependence in premalignant mammary progression. Cancer Res 2003;63:1067-1072 (Pubitemid 36278440)
30. Akaogi K, Nakajima Y, Ito I, et al. KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERα. Oncogene 2009;28:2894-2902
31. Shirley SH, Rundhaug JE, Tian J, et al. Transcriptional regulation of estrogen receptor-α by p53 in human breast cancer cells. Cancer Res 2009;69:3405-3414
32. Chu I. Arnaout A. Loiseau S. Sun J. Seth A. McMahon C. Chun K. Hennessy B. Mills G.B. Nawaz Z. Slingerland J.M. Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer Journal of Clinical Investigation 2007 117 8 2205-2215 http://www.jci.org/cgi/reprint/117/8/2205 DOI 10.1172/JCI21739 32. Chu I, Arnaout A, Loiseau S, et al. Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer. J Clin Invest 2007;117:2205-2215 (Pubitemid 47219565)
33. Mukhopadhyay UK, Eves R, Jia L, Mooney P, Mak AS. p53 suppresses Src-induced podosome and rosette formation and cellular invasiveness through the upregulation of caldesmon. Mol Cell Biol 2009;29:3088-3098
34. Attardi L.D. Jacks T. The role of p53 in tumour suppression: Lessons from mouse models Cellular and Molecular Life Sciences 1999 55 1 48-63 DOI 10.1007/s000180050269 34. Attardi LD, Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci 1999;55:48-63. (Pubitemid 29077854)
35. Jones J.M. Attardi L. Godley L.A. Laucirica R. Medina D. Jacks T. Varmus H.E. Donehower L.A. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis Cell Growth and Differentiation 1997 8 8 829-838 35. Jones JM, Attardi L, Godley LA, et al. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ 1997;8:829-838 (Pubitemid 27355456)
36. Koch J.G. Gu X. Han Y. El-Naggar A.K. Olson M.V. Medina D. Jerry D.J. Blackburn A.C. Peltz G. Amos C.I. Lozano G. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53 Mammalian Genome 2007 18 5 300-309 DOI 10.1007/s00335-007-9028-2 36. Koch JG, Gu X, Han Y, et al. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome 2007;18:300-309 (Pubitemid 47106845)
37. Gunther EJ, Belka GK, Wertheim GB, et al. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J 2002;16:283-292
38. Hruska K.S. Tilli M.T. Ren S. Cotarla I. Kwong T. Li M. Fondell J.D. Hewitt J.A. Koos R.D. Furth P.A. Flaws J.A. Conditional over-expression of estrogen receptor alpha in a transgenic mouse model Transgenic Research 2002 11 4 361-372 DOI 10.1023/A:1016376100186 38. Hruska KS, Tilli MT, Ren S, et al. Conditional over-expression of estrogen receptor α in a transgenic mouse model. Transgenic Res 2002;11:361-372 (Pubitemid 35301747)
39. Jacks T. Remington L. Williams B.O. Schmitt E.M. Halachmi S. Bronson R.T. Weinberg R.A. Tumor spectrum analysis in p53-mutant mice Current Biology 1994 4 1 1-7 DOI 10.1016/S0960-9822(00)00002-6 39. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7. (Pubitemid 2027671)
40. Tilli MT, Frech MS, Steed ME, et al. Introduction of estrogen receptor-α into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol 2003;163:1713-1719
41. Alenzi F.Q.B. Links between apoptosis, proliferation and the cell cycle British Journal of Biomedical Science 2004 61 2 99-102 41. Alenzi FQ. Links between apoptosis, proliferation and the cell cycle. Br J Biomed Sci 2004;61:99-102. (Pubitemid 38879538)
42. Fox EM, Andrade J, Shupnik MA. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 2009;74:622-627
43. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263-1284
44. Vervoorts J, Luscher B. Post-translational regulation of the tumor suppressor p27(KIP1). Cell Mol Life Sci 2008;65:3255-3264
45. Casalini P. Iorio M.V. Berno V. Bergamaschi A. Borresen Dale A.-L. Gasparini P. Orlandi R. Casati B. Tagliabue E. Menard S. Relationship between p53 and p27 expression following HER2 signaling Breast 2007 16 6 597-605 DOI 10.1016/j.breast.2007.05.007, PII S0960977607001063 45. Casalini P, Iorio MV, Berno V, et al. Relationship between p53 and p27 expression following HER2 signaling. Breast 2007;16:597-605. (Pubitemid 350154449)
46. Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status Pathology International 2001 51 2 94-99 DOI 10.1046/j.1440-1827.2001.01173.x 46. Oh YL, Choi JS, Song SY, et al. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int 2001;51:94-99 (Pubitemid 32174734)
47. Slingerland J. Pagano M. Regulation of the Cdk inhibitor p27 and its deregulation in cancer Journal of Cellular Physiology 2000 183 1 10-17 DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I 47. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183:10-17 (Pubitemid 30130220)
48. Chu I, Sun J, Arnaout A, et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2 and p27 proteolysis. Cell 2007;128:281-294
49. Petersen OW, Hoyer PE, van Deurs B. Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res 1987;47:5748-5751
50. Duong V. Boulle N. Daujat S. Chauvet J. Bonnet S. Neel H. Cavailles V. Differential regulation of estrogen receptor α turnover and transactivation by Mdm2 and stress-inducing agents Cancer Research 2007 67 11 5513-5521 http://cancerres.aacrjournals.org/cgi/reprint/67/11/5513 DOI 10.1158/0008-5472.CAN-07-0967 50. Duong V, Boulle N, Daujat S, et al. Differential regulation of estrogen receptor α turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res 2007;67:5513-5521 (Pubitemid 46997293)